Elotuzumab
| Identyfikacja | |
| Inne nazwy i oznaczenia |
HuLuc63, BMS-901608 |
|---|---|
| numer CAS | |
| Klasyfikacja medyczna | |
| ATC | |
Elotuzumab – lek biologiczny o działaniu immunosupresyjnym, obecnie (2012) w fazie badań klinicznych w terapii szpiczaka mnogiego, przeciwciała monoklonalne skierowane przeciwko receptorowi CS1 występującymi na powierzchni komórek szpiczaka mnogiego, receptory te są reprezentowane w minimalny sposób na innych komórkach organizmu[1]. Badania prowadzone są przez firmy Bristol-Myers Squibb i Abbott.
Przypisy
[edytuj | edytuj kod]- ↑ S. Lonial, R. Vij, JL. Harousseau, T. Facon i inni. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.. „J Clin Oncol”. 30 (16), s. 1953-9, Jun 2012. DOI: 10.1200/JCO.2011.37.2649. PMID: 22547589.
Bibliografia
[edytuj | edytuj kod]- AK. Stewart. Novel therapeutics in multiple myeloma.. „Hematology”. 17 Suppl 1, s. S105-8, Apr 2012. DOI: 10.1179/102453312X13336169156131. PMID: 22507794.
- AJ. Jakubowiak, DM. Benson, W. Bensinger, DS. Siegel i inni. Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma.. „J Clin Oncol”. 30 (16), s. 1960-5, Jun 2012. DOI: 10.1200/JCO.2011.37.7069. PMID: 22291084.
- JA. Zonder, AF. Mohrbacher, S. Singhal, F. van Rhee i inni. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.. „Blood”, Dec 2011. DOI: 10.1182/blood-2011-06-360552. PMID: 22184404.
- H. Hata. [Development of novel agents for multiple myeloma; now and the future].. „Rinsho Ketsueki”. 52 (8), s. 603-8, Aug 2011. PMID: 21897065.
- CJ. Fowler, G. Brännström. Reduction in beta-adrenoceptor density in cultured rat glioma C6 cells after incubation with antidepressants is dependent upon the culturing conditions used.. „J Neurochem”. 55 (1), s. 245-50, Jul 1990. PMID: 1972389.
Linki zewnętrzne
[edytuj | edytuj kod]- Badania kliniczne
- A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies., [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT00726869 (ang.).
- Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT01393964 (ang.).
- Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT01441973 (ang.).
- A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT00742560 (ang.).
- PH III Relapse or Refractory MM – Open Label With or Without Elotuzumab (ELOQUENT – 2), [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT01239797 (ang.).
- Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT – 1), [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT01335399 (ang.).
- Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT01478048 (ang.).
- Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma, [w:] ClinicalTrials.gov [online], National Institutes of Health, NCT00425347 (ang.).
